Análisis de la acción Arcus Biosciences Inc (RCUS)RCUSArcus Biosciences Inc

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Arcus Biosciences Inc (RCUS) is not a strong buy. The stock is priced at $22.12, which is close to its 52-week low of $11.30, indicating significant selling pressure. The RSI is at 23.96, suggesting it is oversold, which could attract buyers. However, the forward P/E ratio is 0, and the company has reported negative net income for multiple quarters, with a net income of -128 million USD in Q1 2026. The main risk is the company's ongoing losses, with a net margin of -221.95% in Q2 2026, which raises concerns about its financial health.

3 analysts cover RCUS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 27.44.